Relafen
Drug - Relafen
The trade name of the product as shown on the labeling.
Dosage -
TABLET; ORAL
The product dosage form and route separated by a semi-colon.
Active Ingredient(s) -
Nabumetone
Multiple ingredients are in alphabetical order.
Strength -
500MG
The potency of the active ingredient(s), Nabumetone. May repeat for multiple part products.
Applicant -
GLAXOSMITHKLINE
The firm name holding legal responsibility for Relafen. The firm name is condensed to a maximum twenty character unique string.
New Drug Application (NDA) Number -
019583
The FDA assigned number to Relafen. Format is nnnnnn.
Product Number -
001
The FDA assigned number to identify Relafen. Each strength is a separate product. May repeat for multiple part products. Format is nnn.
Therapeutic Equivalence (TE) Code -
AB
The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products.
Approval Date -
Dec 24, 1991
The date Relafen was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982".
Reference Listed Drug (RLD) -
No
The pioneer or innovator of Relafen. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No.
Type -
RX
The group or category of approved drugs Relafen is in. Format is RX, OTC, DISCN.
Applicant Full Name -
Glaxosmithkline
The full name of the firm holding legal responsibility for the new application of Relafen.
Relafen
|
